Amended Statement of Beneficial Ownership (sc 13d/a)
May 30 2019 - 6:07AM
Edgar (US Regulatory)
United States
Securities and Exchange Commission
Washington, D.C. 20549
SCHEDULE 13D
(Rule
13d-101)
Information to be Included in Statements Filed Pursuant to §
240.13d-1(a)
and
Amendments Thereto Filed Pursuant to §
240.13d-2(a)
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
Eidos
Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.001
(Title of Class of Securities)
28249H104
(CUSIP Number)
Brian Stephenson
BridgeBio Pharma, Inc.
421 Kipling Street,
Palo
Alto, CA 94301
(650)
391-9740
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
May 24, 2019
(Date
of Event Which Requires Filing of This Statement)
If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule
13d-1(e),
Rule
13d-1(f)
or Rule
13d-1(g),
check the following box. ☐
Note:
Schedules filed in paper format shall
include a signed original and five copies of the schedule, including all exhibits. See Rule
13d-7(b)
for other parties to whom copies are to be sent.
*
|
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form
with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
|
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities
Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
CUSIP No. 28249H104
|
|
13D
|
|
Page
2
of 4 pages
|
|
|
|
|
|
|
|
1
|
|
Names of Reporting Persons
BridgeBio Pharma, Inc.
|
2
|
|
Check the Appropriate Box
if a Member of a Group
(a) ☐ (b) ☐
|
3
|
|
SEC Use Only
|
4
|
|
Source of Funds (See
Instructions)
OO
|
5
|
|
Check if disclosure of
legal proceedings is required pursuant to Items 2(d) or 2(e)
☐
|
6
|
|
Citizenship or Place of
Organization
Delaware
|
|
|
|
|
|
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
|
7
|
|
Sole Voting Power
23,693,148
|
|
8
|
|
Shared Voting Power
0
|
|
9
|
|
Sole Dispositive Power
23,693,148
|
|
10
|
|
Shared Dispositive Power
0
|
|
|
|
|
|
|
|
11
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
23,693,148
|
12
|
|
Check if the Aggregate
Amount in Row (11) Excludes Certain Shares
☐
|
13
|
|
Percent of Class
Represented by Amount in Row (11)
64.3%
|
14
|
|
Type of Reporting
Person
CO (Delaware corporation)
|
|
|
|
|
|
CUSIP No. 28249H104
|
|
13D
|
|
Page
3
of 4 pages
|
EXPLANATORY NOTE
This Amendment No. 4 amends the Schedule 13D (as amended, the Schedule 13D) originally filed by BridgeBio Pharma LLC (the Original
Reporting Person) relating to the Common Stock, par value $0.001 per share (the Common Stock), of Eidos Therapeutics, Inc., a Delaware corporation (the Issuer), whose principal executive offices are located at 101
Montgomery Street, Suite 2550, San Francisco, California 94104. Except as specifically set forth herein, the Schedule 13D remains unmodified.
On
May 17, 2019, the Original Reporting Person formed BridgeBio Pharma, Inc., a Delaware corporation (the Reporting Person). Prior to the completion of the Reporting Persons initial public offering, the Original Reporting Person
intends to complete a series of transactions pursuant to which it will form BridgeBio Pharma Merger Sub LLC (Merger Sub LLC), an entity that will be a wholly-owned subsidiary of the Reporting Person. Merger Sub LLC will be merged with
and into the Original Reporting Person prior to the completion of the Reporting Persons initial public offering, with the Original Reporting Person being the surviving entity as a wholly-owned subsidiary of the Reporting Person. As part of
this merger, the unitholders of the Original Reporting Person will exchange their units in the Original Reporting Person for shares of common stock of the Reporting Person.
Item 3. Source and Amount of Funds or Other Consideration.
Item 3 of the Schedule 13D is supplemented by the addition of the following:
In May 2019, the Original Reporting Person purchased 1,103,848 shares of Common Stock for $25.9345 per share in a privately negotiated transaction. The
Original Reporting Person obtained the funds to purchase the shares of Common Stock through capital contributions from its members.
Item 5.
Interest in Securities of the Issuer.
Item 5 of the Schedule 13D is amended by restating the items disclosed under (a) (b) thereof as follows:
The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially
owned by the Original Reporting Person, as well as the number of shares of Common Stock as to which the Original Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or
to direct the disposition, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 36,827,549 shares of Common Stock outstanding as of May 1, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reporting Person
|
|
Amount
beneficially
owned
|
|
|
Percent
of class
|
|
|
Sole power
to vote or
to direct
the vote
|
|
|
Shared
power to
vote or to
direct the
vote
|
|
|
Sole power
to dispose
or to direct
the
disposition
|
|
|
Shared
power to
dispose or to
direct the
disposition
|
|
BridgeBio Pharma LLC
|
|
|
23,693,148
|
|
|
|
64.3
|
%
|
|
|
23,693,148
|
|
|
|
0
|
|
|
|
23,693,148
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Original Reporting Person is the record holder of 23,693,148 shares of Common Stock.
|
|
|
|
|
CUSIP No. 28249H104
|
|
13D
|
|
Page
4
of 4 pages
|
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date:
May 29, 2019
|
|
|
BridgeBio Pharma, Inc.
|
|
|
By:
|
|
/s/ Neil Kumar
|
Name:
|
|
Neil Kumar
|
Title:
|
|
Chief Executive Officer
|
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Sep 2023 to Sep 2024